Light Horse Therapeutics

Executive Summary

Light Horse Therapeutics is a preclinical-stage biotechnology company pioneering small molecule and RNA-based therapeutics to target genetic drivers of disease, with a focus on oncology and genetic disorders. Founded in 2020 and headquartered in San Diego, the company has raised $62 million to advance its innovative platform that modulates RNA biology and protein function. By addressing high unmet medical needs through novel mechanisms, Light Horse aims to develop treatments for serious conditions at the genetic level. Despite being in the preclinical phase, its unique approach and solid funding position it as a promising player in the RNA therapeutics and precision medicine space. Key upcoming milestones include potential IND-enabling studies and further pipeline advancement.

Upcoming Catalysts (preview)

• Q2 2027Announcement of lead program IND filing or preclinical data40% success
• H2 2026Strategic partnership or licensing deal for platform or pipeline30% success
• Q1 2027Series B or additional financing round50% success